פורסיגה 5 מ"ג - Forxiga 5 mg

× ×ª×× × ×ª×¨××¤×

××¦××ª

××××¨××

××××¢ × ××¡×£

×¡×¨××× ××

××¨×¦×××ª

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

××× ×× ×× × ××¡×¤××

×¤××¨×¡××× 10 ×"× - Forxiga 10 mg

×§×××¦× ×¤×¨××§××××××ª (ATC4)

A10BK
Sodium-glucose co-transporter 2 (SGLT2) inhibitors

××¨××× ×¤×¢×× (ATC5)

Dapagliflozin propanediol 6.150 MG/DOSE âA10BK01

×¦××¨×ª ××ª×

×¤××× - PER OS

×¦××¨×ª ××× ××

××××××ª ××¦××¤××ª ×¤×××, FILM COATED TABLETS
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Forxiga is indicated:- in adults aged 18 years and older for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise â¢as monotherapy when metformin is considered inappropriate due to intolerance. â¢in addition to other medicinal products for the treatment of type 2 diabetes. - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction- to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. Limitations of Use -FORXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FORXIGA is not expected to be effective in these populations.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

12/01/2017

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××
×× ×¡×¤××§×ª ×× ×ª×¡××× ××ª (××¨×××ª ×ª×¤×§×× NYHA II-IV) ×××××× ×¢× ××§××¢ ×¤×××× ×©×××¨.	17/03/2024	×× ×××× ××		×× ×¡×¤××§×ª ×× ×ª×¡××× ××ª
eGFR ××¢×¨× 30 ×"×/××§×/1.73 ×"×¨ ×××¢××, ×× ××¢×¨× ×××× ×××ª×¨ ×××ª×× ××ª× ×× ××¨××©××.	17/03/2024	×× ×××§×¨×× ××××××		×¡×××¨×ª ×¡×× 2, Diabetes
××××ª ×××× ××¨×× ××ª, ×××××× ×××××¤××× ××ª××©××¨ ×××©×¤××ª ××¢××× ACE ×× ARB ×××¢×× ×× ×¢× ××× ××××, ×××ª×× ××ª× ×× ××¨××©××: 1. ×××¡ ××××××× / ×§×¨×××× ×× ××©×ª× ×©× 200 ×"×/××¨× ×××¢×× ×-eGFR ××× 25 45 ×-75 90 ×"×/××§×. 2. eGFR ××× 20-45 ××× ×ª×××ª ××¢×¨×× ×××¡ ××××××× / ×§×¨×××× ×× ××©×ª×.	17/03/2024	×× ×××× ××		eGFR
×. ×¡×××¨×ª ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. HbA1c ××¢×¨× 7.0% ×××¢××, ×¢× ××£ ×××¤×× ×§××× ×××××ª×. 2. eGFR ××¢×¨× 45 ×"×/××§×/1.73 ×"×¨ ×××¢××, ×× ××¢×¨× ×××× ×××ª×¨ ×××ª×× ××ª× ×× ××¨××©××. 3. ×××× × ×©× ××× ××××: ×. ×××× ××©×¨××¨ ××× ×. × ××ª×× ××¢×§×¤×× (CABG) ×. ××××ª ×× ×××¡××××ª. ×. ××××ª ×××× ××¨×× ××ª ××××××¨×ª ×××× ××××, ×××ª×× ××ª× ×× ××¨××©××: 1. ×××¡ ××××××× / ×§×¨××××× ×× ××¢× 30 ×"×/××¨×; 3. eGFR × ××× ×-60 ×"×/××§×.	01/02/2023	×× ×××§×¨×× ××××××	DAPAGLIFLOZIN, ERTUGLIFLOZIN (L-PGA), EMPAGLIFLOZIN	×¡×××¨×ª ×¡×× 2, Diabetes
×××¤×× ××××× ××××ª ×××× ××¨×× ××ª ×¢× ×××¡ ××××××× / ×§×¨×××× ×× ××©×ª× ×©× 200 ×"×/××¨× ×××¢×× ×-eGFR ××× 25 ×-75 ×"×/××§×, ×××××¤××× ××ª××©××¨ ×××©×¤××ª ××¢××× ACE ×× ARB.	01/02/2023	× ×¤×¨××××××		Chronic kidney disease, CKD, ××××ª ×××× ××¨×× ××ª
×××¤×× ××××× ××××ª ×××× ××¨×× ××ª ×©××× × ×¡×××¨×ª××× ×× ×¡××××× ××× ×¡×¤××§×ª ××, ×¢× ×××¡ ××××××× / ×§×¨×××× ×× ××©×ª× ×©× 200 ×"×/××¨× ×××¢×× ×-eGFR ××× 25 ×-75 ×"×/××§×, ×××××¤××× ××ª××©××¨ ×××©×¤××ª ××¢××× ACE ×× ARB.	03/02/2022	× ×¤×¨××××××		Chronic kidney disease, CKD, ××××ª ×××× ××¨×× ××ª
×× ×¡×¤××§×ª ×× ×ª×¡××× ××ª (××¨×××ª ×ª×¤×§×× NYHA II-IV) ×××××× ×¢× ××§××¢ ×¤×××× ××¨×× (HFrEF) ××¢×¨× 40% ××××, ××©×¨ × ××ª×¨× ×¡×××¤××××××× ×××¨××ª ×××¦×× ×××¤×× ××××× ×××××ª×. ××¢× ××× ×× ×××¤×× ××××× ××××× ×ª×¨××¤××ª ×××©×¤××ª ××¢××× RAS (××¢××× ACE, ××©×¤××ª ARB) ××××¡×× ×××.	01/03/2021	×× ×××× ××		×× ×¡×¤××§×ª ××
×¡×××¨×ª ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. HbA1c ××¢×¨× 7.0% ×××¢××, ×¢× ××£ ×××¤×× ×§××× ×××××ª×. 2. eGFR ××¢×¨× 45 ×"×/××§×/1.73 ×"×¨ ×××¢××, ×× ××¢×¨× ×××× ×××ª×¨ ×××ª×× ××ª× ×× ××¨××©××. 3. ×××× × ×©× ××× ××××: ×. ×××× ××©×¨××¨ ××× ×. × ××ª×× ××¢×§×¤×× (CABG) ×. ××××ª ×× ×××¡××××ª. ×. ×× ×¡×¤××§× ×××××ª××ª ××××××¨×ª ×××× ××××, ×××ª×× ××ª× ×× ××¨××©××: 1. eGFR × ××× ×-90 ×"×/××§× ××××§×¨×××××××× ××¨×× (×××××¨×ª ××××¡ ×§×¨×××× ×× ××××××× ××¢× 300 ×"×/××¨×). 2. eGFR × ××× ×-90 ×"×/××§× ××××§×¨×××××××× ××¨×× (×××××¨×ª ××××¡ ×§×¨×××× ×× ××××××× ××¢× 30 ×"×/××¨×). 3. eGFR × ××× ×-60 ×"×/××§×.	01/03/2021	×× ×××§×¨×× ××××××	DAPAGLIFLOZIN, ERTUGLIFLOZIN (L-PGA), EMPAGLIFLOZIN	×¡×××¨×ª ×¡×× 2
×¡×××¨×ª ×¡×× 2 ×××××× ××¢×× ×× ×¢× ×× ×××: ×. HbA1c ××¢×¨× 7% ×××¢××, ×¢× ××£ ×××¤×× ×§××× ×××××ª×. ×. eGFR ××¢×¨× 45 ×"×/××§×/1.73 ×"×¨ ×××¢××, ×× ××¢×¨× ×××× ×××ª×¨ ×××ª×× ××ª× ×× ××¨××©××. ×. ×××× × ×©× ××× ××××: 1. ×××× ××©×¨××¨ ××× 2. × ××ª×× ××¢×§×¤×× (CABG) 3. ××××ª ×× ×××¡××××ª. 4. ×× ×¡×¤××§× ×××××ª××ª ××××××¨×ª ×××× ××××, ×××ª×× ××ª× ×× ××¨××©××: ×. eGFR × ××× ×-90 ×"×/××§× ××××§×¨×××××××× ××¨×× (×××××¨×ª ××××¡ ×§×¨×××× ×× ××××××× ××¢× 300 ×"×/××¨×). ×. eGFR × ××× ×-60 ×"×/××§×.	30/01/2020	×× ×××§×¨×× ××××××	DAPAGLIFLOZIN, ERTUGLIFLOZIN (L-PGA), EMPAGLIFLOZIN	×¡×××¨×ª ×¡×× 2, Diabetes
×¡×××¨×ª ×¡×× 2 ×××××× ××¢×× ×× ×¢× ×× ×××: ×. HbA1c ××¢×¨× 7.5% ×××¢××, ×¢× ××£ ×××¤×× ×§××× ×××××ª×. ×. eGFR ××¢×¨× 45 ×"×/××§×/1.73 ×"×¨ ×××¢××, ×× ××¢×¨× ×××× ×××ª×¨ ×××ª×× ××ª× ×× ××¨××©××. ×. ×××× × ×©× ××× ××××: 1. ×××× ××©×¨××¨ ××× 2. × ××ª×× ××¢×§×¤×× (CABG) 3. ××××ª ×× ×××¡××××ª.
×¡×××¨×ª ×¡×× 2 ×××××× ××¢×× ×× ×¢× ×× ×××: ×. HbA1c ××¢×¨× 7% ×××¢××, ×¢× ××£ ×××¤×× ×§××× ×××××ª×. ×. eGFR ××¢×¨× 45 ×"×/××§×/1.73 ×"×¨ ×××¢××, ×× ××¢×¨× ×××× ×××ª×¨ ×××ª×× ××ª× ×× ××¨××©××. ×. ×××× × ×©× ××× ××××: 1. ×××× ××©×¨××¨ ××× 2. × ××ª×× ××¢×§×¤×× (CABG) 3. ××××ª ×× ×××¡××××ª.

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×××§×¨×× ××××:

×. ×¡×××¨×ª ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××:

1. HbA1c ××¢×¨× 7.0% ×××¢××, ×¢× ××£ ×××¤×× ×§××× ×××××ª×.

2. eGFR ××¢×¨× 45 30 ×"×/××§×/1.73 ×"×¨ ×××¢××, ×× ××¢×¨× ×××× ×××ª×¨ ×××ª×× ××ª× ×× ××¨××©××.

×. × ××ª×× ××¢×§×¤×× (CABG)

×. ××××ª ×× ×××¡××××ª.

1. ×××¡ ××××××× / ×§×¨××××× ×× ××¢× 30 ×"× / ××¨×

2. eGFR × ××× ×-60 ×"×/××§×.

×. ×× ×¡×¤××§×ª ×× ×ª×¡××× ××ª (××¨×××ª ×ª×¤×§×× NYHA II-IV) ×××××× ×¢× ××§××¢ ×¤×××× ××¨×× (HFrEF) ××¢×¨× ×©× 40% ××××, ××©×¨ × ××ª×¨× ×¡×××¤××××××× ×××¨××ª ×××¦×× ×××¤×× ××××× ×××××ª×.
××¢× ××× ×× ×××¤×× ××××× ××××× ×ª×¨××¤××ª ×××©×¤××ª ××¢××× RAS (××¢××× ACE, ××©×¤××ª ARB) ××××¡×× ×××.

×. ××××ª ×××× ××¨×× ××ª, ×××××× ×××××¤××× ××ª××©××¨ ×××©×¤××ª ××¢××× ACE ×× ARB ×××¢×× ×× ×¢× ××× ××××, ×××ª×× ××ª× ×× ××¨××©××:

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 29.02.2024

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× ×¢××¨××ª 29.02.2024 ×¢××× ××¦×¨×× ×× ××××ª - Patient information leafletâ 31.07.2023 ×¢××× ××¦×¨×× ×¢×¨×××ª - ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© â31.07.2023

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×¤××¨×¡××× 5 ×"× ×××××¨ ××©×¨× ×××¨××××ª ×¤××¨×¡××× 5 ×"× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	ASTRA ZENECA AB., SWEDEN
×©× ××¢× ××¨××©××	ASTRA ZENECA (ISRAEL) LTD
×¨××©×××	×ª××¨×× ×××©×: 10/2013. ×¨××©××× ××ª××¨××: 08/2014
×ª××¨×× ×¢×××× ×××¨××	14/05/19

××××¨××

××¦×¤××× ×××××¢ ×××¨×× ××¨××¤××× ××© ××××× ×¡ ×××©××× ×. ×× ××× × ×¨×©×× ××× ×¡ ×××¨×©×× ××¨××¤××× ××× ×©× ××§×¦××¢××ª ×¨×¤×××××.

השינוי האחרון נעשה בֹ־23 בספטמבר 2025 ב־02:54

פורסיגה 5 מ"ג - Forxiga 5 mg

ויקיתרופות